|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 471/04 | |
| A61P 11/00 | |||
| A61K 31/437 | |||
| A61K 31/397 |
| (11) | Number of the document | 3592742 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18711796.5 |
| Date of filing the European patent application | 2018-03-08 | |
| (97) | Date of publication of the European application | 2020-01-15 |
| (45) | Date of publication and mention of the grant of the patent | 2021-05-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2018/021489 |
| Date | 2018-03-08 |
| (87) | Number | WO 2018/165392 |
| Date | 2018-09-13 |
| (30) | Number | Date | Country code |
| 201762469073 P | 2017-03-09 | US |
| (72) |
FATHEREE, Paul R., US
BRANDT, Gary E.L., US
SMITH, Cameron, US
SULLIVAN, Steven D.E., US
VAN ORDEN, Lori Jean, US
KLEINSCHEK, Melanie A., US
CRATER, Glenn D., US
|
| (73) |
Theravance Biopharma R&D IP, LLC,
901 Gateway Boulevard, South San Francisco, CA 94080,
US
|
| (54) | JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE |
| JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE |